These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 35706413)
1. Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition. Alvarez-Breckenridge C; Markson SC; Stocking JH; Nayyar N; Lastrapes M; Strickland MR; Kim AE; de Sauvage M; Dahal A; Larson JM; Mora JL; Navia AW; Klein RH; Kuter BM; Gill CM; Bertalan M; Shaw B; Kaplan A; Subramanian M; Jain A; Kumar S; Danish H; White M; Shahid O; Pauken KE; Miller BC; Frederick DT; Hebert C; Shaw M; Martinez-Lage M; Frosch M; Wang N; Gerstner E; Nahed BV; Curry WT; Carter B; Cahill DP; Boland GM; Izar B; Davies MA; Sharpe AH; Suvà ML; Sullivan RJ; Brastianos PK; Carter SL Cancer Immunol Res; 2022 Aug; 10(8):996-1012. PubMed ID: 35706413 [TBL] [Abstract][Full Text] [Related]
2. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases. Hilbers ML; Dimitriou F; Lau P; Bhave P; McArthur GA; Zimmer L; Kudura K; Gérard CL; Levesque MP; Michielin O; Dummer R; Cheng PF; Mangana J Eur J Cancer; 2021 Oct; 156():149-163. PubMed ID: 34454317 [TBL] [Abstract][Full Text] [Related]
3. Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Fischer GM; Jalali A; Kircher DA; Lee WC; McQuade JL; Haydu LE; Joon AY; Reuben A; de Macedo MP; Carapeto FCL; Yang C; Srivastava A; Ambati CR; Sreekumar A; Hudgens CW; Knighton B; Deng W; Ferguson SD; Tawbi HA; Glitza IC; Gershenwald JE; Vashisht Gopal YN; Hwu P; Huse JT; Wargo JA; Futreal PA; Putluri N; Lazar AJ; DeBerardinis RJ; Marszalek JR; Zhang J; Holmen SL; Tetzlaff MT; Davies MA Cancer Discov; 2019 May; 9(5):628-645. PubMed ID: 30787016 [TBL] [Abstract][Full Text] [Related]
4. Impact of Sequencing Radiation Therapy and Immune Checkpoint Inhibitors in the Treatment of Melanoma Brain Metastases. Pomeranz Krummel DA; Nasti TH; Izar B; Press RH; Xu M; Lowder L; Kallay L; Rupji M; Rosen H; Su J; Curran W; Olson J; Weinberg B; Schniederjan M; Neill S; Lawson D; Kowalski J; Khan MK; Sengupta S Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):157-163. PubMed ID: 32057994 [TBL] [Abstract][Full Text] [Related]
5. The role of systemic therapy in melanoma brain metastases: a narrative review. Saleem K; Davar D Chin Clin Oncol; 2022 Jun; 11(3):24. PubMed ID: 35818856 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of radio-immunotherapy sequence on immunological responses and clinical outcomes in patients with melanoma brain metastases (ELEKTRA). Hassel JC; Schank TE; Smetak H; Mühlbauer J; Salzmann M; Machiraju D; Menzer C; Lang K; König L; Haefner MF; Hülsmeyer I; Kohler C; Spang R; Enk A; Debus J; Beckhove P Oncoimmunology; 2022; 11(1):2066609. PubMed ID: 35481285 [TBL] [Abstract][Full Text] [Related]
7. Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases. Smalley I; Chen Z; Phadke M; Li J; Yu X; Wyatt C; Evernden B; Messina JL; Sarnaik A; Sondak VK; Zhang C; Law V; Tran N; Etame A; Macaulay RJB; Eroglu Z; Forsyth PA; Rodriguez PC; Chen YA; Smalley KSM Clin Cancer Res; 2021 Jul; 27(14):4109-4125. PubMed ID: 34035069 [TBL] [Abstract][Full Text] [Related]
8. Advances in the systemic treatment of melanoma brain metastases. Glitza Oliva IC; Schvartsman G; Tawbi H Ann Oncol; 2018 Jul; 29(7):1509-1520. PubMed ID: 29790899 [TBL] [Abstract][Full Text] [Related]
9. Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma. Schvartsman G; Ma J; Bassett RL; Haydu LE; Amaria RN; Hwu P; Wong MK; Hwu WJ; Diab A; Patel SP; Davies MA; Hamerschlak N; Tawbi HA; Glitza Oliva IC Cancer; 2019 Dec; 125(23):4193-4202. PubMed ID: 31398264 [TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of melanoma brain metastases treated with nivolumab and ipilimumab alone versus nivolumab and ipilimumab with stereotactic radiosurgery. Tang JD; Mills MN; Nakashima J; Dohm AE; Khushalani NI; Forsyth PA; Vogelbaum MA; Wuthrick EJ; Yu HM; Oliver DE; Liu JKC; Ahmed KA J Neurooncol; 2024 Feb; 166(3):431-440. PubMed ID: 38310157 [TBL] [Abstract][Full Text] [Related]
11. A single-center retrospective analysis of prognoses in patients with melanoma brain metastases and effectiveness of treatment in Japan. Wada S; Ogata D; Kashihara T; Okuma K; Eto H; Nakano E; Takahashi A; Namikawa K; Igaki H; Yamazaki N Cancer Med; 2023 Dec; 12(24):21933-21943. PubMed ID: 38083908 [TBL] [Abstract][Full Text] [Related]
12. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice. Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591 [TBL] [Abstract][Full Text] [Related]
13. Dissecting the treatment-naive ecosystem of human melanoma brain metastasis. Biermann J; Melms JC; Amin AD; Wang Y; Caprio LA; Karz A; Tagore S; Barrera I; Ibarra-Arellano MA; Andreatta M; Fullerton BT; Gretarsson KH; Sahu V; Mangipudy VS; Nguyen TTT; Nair A; Rogava M; Ho P; Koch PD; Banu M; Humala N; Mahajan A; Walsh ZH; Shah SB; Vaccaro DH; Caldwell B; Mu M; Wünnemann F; Chazotte M; Berhe S; Luoma AM; Driver J; Ingham M; Khan SA; Rapisuwon S; Slingluff CL; Eigentler T; Röcken M; Carvajal R; Atkins MB; Davies MA; Agustinus A; Bakhoum SF; Azizi E; Siegelin M; Lu C; Carmona SJ; Hibshoosh H; Ribas A; Canoll P; Bruce JN; Bi WL; Agrawal P; Schapiro D; Hernando E; Macosko EZ; Chen F; Schwartz GK; Izar B Cell; 2022 Jul; 185(14):2591-2608.e30. PubMed ID: 35803246 [TBL] [Abstract][Full Text] [Related]